Gatekeeping procedures in dose-response clinical trials based on the Dunnett test

被引:22
作者
Dmitrienko, Alex
Offen, Walt
Wang, Ouhong
Xia, Dan
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Wyeth Global Biostat, Collegeville, PA USA
关键词
multiple testing; gatekeeping tests;
D O I
10.1002/pst.190
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This paper discusses multiple testing procedures in dose-response clinical trials with primary and secondary endpoints. A general gatekeeping framework for constructing multiple tests is proposed, which extends the Dunnett test [Journal of the American Statistical Association 1955; 50: 1096-1121] and Bonferroni-based gatekeeping tests developed by Dmitrienko et al. [Statistics in Medicine 2003; 22:2387-2400]. The proposed procedure accounts for the hierarchical structure Of the testing problem; for example, it restricts testing of secondary endpoints to the doses for which the primary endpoint is significant. The multiple testing approach is illustrated using a dose-response clinical trial in patients with diabetes. Monte-Carlo simulations. demonstrate that the proposed procedure provides a power advantage over the Bonferroni gatekeeping procedure. The power gain generally increases with increasing correlation among the endpoints, especially when all primary dose-control comparisons are significant. Copyright (C) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:19 / 28
页数:10
相关论文
共 16 条